Novo NVO announced new real-world data from the COMPETE SWITCH Cardiovascular (CV) study comparing treatment strategies in adults with type II diabetes (T2D) who were already receiving a 1-mg dose of Ozempic (semaglutide) injection. The analysis found that patients who increased their Ozempic dose had a lower observed risk of major adverse cardiovascular events (MACE) than those who switched to Lilly's LLY Mounjaro (tirzepatide). Ozempic and Mounjaro are competing therapies in the U.S. diabetes market. Ozempic is a once-weekly GLP-1 receptor agonist developed by Novo.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.